SequelSEC

enGene Therapeutics Inc. ENGN

Biological Products, (No Diagnostic Substances) · CIK 0001980845 · Fiscal year ends 1031

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2026-07-31
Operating income
-$34.01M
Fiscal year ended 2026-07-31
Free cash flow
-$18.95M
Fiscal year ended 2026-07-31

Valuation, from the filing

Public float$154.18MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-04-30
Float per share$2.30Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / equity0.9×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-04-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-10-31 — the year that filing covered.

How this compares in its industry

Percentile among the Biological Products, (No Diagnostic Substances) filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Current ratio6.30x62th

enGene Therapeutics Inc. (ENGN) reported net income of -$32.50M for the fiscal year ended 2026-07-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from enGene Therapeutics Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

enGene Therapeutics Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-07-312026-04-302026-01-312025-10-312025-07-312025-04-302025-01-312024-10-312024-07-312024-04-30
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$34.01MUnavailableUnavailable-$39.48M-$29.95MUnavailableUnavailable-$17.46M-$16.76MUnavailable
Net income-$32.50MUnavailableUnavailable-$37.88M-$28.99MUnavailableUnavailable-$15.30M-$14.15MUnavailable
Research & development$20.09MUnavailableUnavailable$31.72M$22.58MUnavailableUnavailable$11.27M$11.55MUnavailable
Weighted-average diluted sharesshares 69.73MUnavailableUnavailableUnavailableshares 51.10MUnavailableUnavailableUnavailableshares 44.17MUnavailable
Pretax income-$32.50MUnavailableUnavailable-$38.38M-$28.75MUnavailableUnavailable-$15.28M-$14.18MUnavailable
Income tax expense$0UnavailableUnavailable-$497.00K$239.00KUnavailableUnavailable$19.00K-$29.00KUnavailable
Diluted EPS$-0.47UnavailableUnavailableUnavailable$-0.57UnavailableUnavailableUnavailable$0.32Unavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$13.92MUnavailableUnavailable$7.76M$7.37MUnavailableUnavailable$6.18M$5.21MUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

enGene Therapeutics Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-07-312026-04-302026-01-312025-10-312025-07-312025-04-302025-01-312024-10-312024-07-312024-04-30
Cash & equivalents$41.02MUnavailableUnavailable$50.15M$32.62MUnavailableUnavailable$173.00M$257.68MUnavailable
Total assets$288.32MUnavailableUnavailable$221.47M$245.55MUnavailableUnavailable$311.17M$266.88MUnavailable
Current assets$277.90MUnavailableUnavailable$201.39M$211.31MUnavailableUnavailable$247.36M$262.69MUnavailable
Total liabilities$58.03MUnavailableUnavailable$53.76M$44.88MUnavailableUnavailable$38.56M$36.55MUnavailable
Current liabilities$27.21MUnavailableUnavailable$31.98M$20.44MUnavailableUnavailable$14.66M$13.46MUnavailable
Total equity incl. NCI$230.29MUnavailableUnavailable$167.71M$200.67MUnavailableUnavailable$272.61M$230.33MUnavailable
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$2.54MUnavailableUnavailable$6.69M$2.38MUnavailableUnavailable$1.41M$2.86MUnavailable

Cash flow

enGene Therapeutics Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-07-312026-04-302026-01-312025-10-312025-07-312025-04-302025-01-312024-10-312024-07-312024-04-30
Operating cash flow-$18.95MUnavailableUnavailable-$24.96M-$25.63MUnavailableUnavailable-$19.57M-$7.18MUnavailable
Capital expenditures$0UnavailableUnavailable$437.00K$704.00KUnavailableUnavailable$238.00K$2.00KUnavailable
Investing cash flow$30.12MUnavailableUnavailable$40.50M$1.38MUnavailableUnavailable-$125.27M-$2.00KUnavailable
Financing cash flow$23.00KUnavailableUnavailable$1.99M-$667.00KUnavailableUnavailable$60.16M$51.00KUnavailable
Net change in cash$11.20MUnavailableUnavailable$17.53M-$24.92MUnavailableUnavailable-$84.67M-$7.13MUnavailable
Stock-based compensation$7.81MUnavailableUnavailable$2.61M$2.58MUnavailableUnavailable$1.66M$1.46MUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$100.00KUnavailableUnavailable$200.00K$100.00KUnavailableUnavailable$100.00K$100.00KUnavailable

Derived

enGene Therapeutics Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-07-312026-04-302026-01-312025-10-312025-07-312025-04-302025-01-312024-10-312024-07-312024-04-30
Free cash flow-$18.95MUnavailableUnavailable-$25.40M-$26.34MUnavailableUnavailable-$19.81M-$7.18MUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio10.21xUnavailableUnavailable6.30x10.34xUnavailableUnavailable16.87x19.52xUnavailable
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ENGN in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-09-08View SEC filing
10-Q · Filed 2026-06-15View SEC filing
10-Q · Filed 2026-03-09View SEC filing
10-K · Filed 2025-12-22View SEC filing
10-Q · Filed 2025-09-11View SEC filing
10-Q · Filed 2025-06-12View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Reconciliation checks needing review

17 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationinconsistent2026-04-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2026-04-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2026-01-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2026-01-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2025-04-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2025-04-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2025-01-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2025-01-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2024-04-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2024-04-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2024-01-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2024-01-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.